Rosiglitazone decreases albuminuria in type 2 diabetic patients.
Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Kidney Int. 2007 Dec;72(11):1367-73
No Comments
Posted in Diabetes
Archive for the ‘Diabetes’ Category
December 1, 2007
November 1, 2007
Management of Glycemia in Patients With Diabetes Mellitus and CKD.
Lubowsky ND, Siegel R, Pittas AG. Am J Kidney Dis. 2007 Nov;50(5):865-79
No Comments
Posted in Diabetes
October 1, 2007
Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence.
. .
No Comments
Posted in Diabetes
July 22, 2007
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.
KDOQI. Am J Kidney Dis. 2007 Feb;49(2 Suppl 2):S12-154
Authoritative guidelines by KDOQI.
April 1, 2007
Glycated Albumin Is a Better Glycemic Indicator than Glycated Hemoglobin Values in Hemodialysis Patients with Diabetes: Effect of Anemia and Erythropoietin Injection.
Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y, Osaka CKD Expert Research Group. J Am Soc Nephrol. 2007 Mar;18(3):896-903
No Comments
Posted in Diabetes
March 1, 2007
How Reliable Is Estimation of Glomerular Filtration Rate at Diagnosis of Type 2 Diabetes?
Chudleigh RA, Dunseath G, Evans W, Harvey JN, Evans P, Ollerton R, Owens DR. Diabetes Care. 2007 Feb;30(2):300-5
No Comments
Posted in Diabetes
January 1, 2007
Effect of Intensive Blood Pressure Control With Valsartan on Urinary Albumin Excretion in Normotensive Patients With Type 2 Diabetes.
Estacio RO, Coll JR, Tran ZV, Schrier RW. Am J Hypertens. 2006 Dec;19(12):1241-8
No Comments
Posted in Diabetes
October 1, 2006
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Clin J Am Soc Nephrol. 2006 Sep;1(5):940-51
No Comments
Posted in Diabetes
September 20, 2001
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. N Engl J Med. 2001 Sep 20;345(12):851-60
Landmark randomized controlled trial which showed that, compared with amlodipine, irbesartan reduced the primary composite end point of a doubling of the base-line serum creatinine concentration, the development of end-stage renal disease, or death from any cause in patients with diabetic nephropathy.
1 Comment
Posted in Chronic Kidney Disease, Diabetes, RAS Blockade
September 20, 2001
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. N Engl J Med. 2001 Sep 20;345(12):861-9
A landmark randomized controlled trial which showed that, compared to placebo, losartan reduced the incidence of a doubling of the serum creatinine concentration and end-stage renal disease.
No Comments
Posted in Chronic Kidney Disease, Diabetes, RAS Blockade
Recent Comments